$4,999.00 – $6,999.00
Zejula is a targeted drug from the PARP inhibitor group, prescribed for locally advanced or metastatic epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer (peritoneal).
The drug is also approved for the treatment of castration-resistant metastatic prostate cancer, in combination with Abiraterone and prednisone.
Active ingredient: Niraparib
Prescription medicine
| Количество таблеток | 56 Tab, 84 Tab |
|---|
